FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant polypeptides with phospholipase C activity, and can be used for degumming oils and fats. Disclosed is phospholipase C mutant polypeptide, amino acid sequence of which is at least 95% identical to SEQ ID NO: 4 and is characterized by the presence of proline, isoleucine, threonine, glycine and tyrosine in positions of amino acid residues, corresponding to positions 6, 8, 10, 104 and 205 in SEQ ID NO: 4, respectively.
EFFECT: invention enables to obtain mutant phospholipase C with high thermal stability.
10 cl, 3 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUTANT OF PHOSPHOLIPASE WITH HIGH ENZYMATIC ACTIVITY | 2019 |
|
RU2818353C2 |
| METHOD FOR REMOVAL OF RESINOUS SUBSTANCES FROM VEGETABLE OIL AND ITS REFINING | 2018 |
|
RU2772452C2 |
| NEW POLYPEPTIDE AND METHOD OF PRODUCING L-LEUCINE USING ITS | 2021 |
|
RU2811433C1 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| VARIANT OF GLUTAMATE CYSTEINE LIGASE AND METHOD OF PRODUCING GLUTATHIONE USING SAME | 2021 |
|
RU2821273C1 |
| ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| CHIMERIC PROTEIN COMPOSED OF AN NGF ANTAGONIST DOMAIN AND A TNFΑ ANTAGONIST DOMAIN | 2015 |
|
RU2788122C2 |
